Chylothorax Diagnosis: A Comprehensive Guide for Clinicians

Introduction

Chylothorax, characterized by the abnormal accumulation of chyle within the pleural cavity, arises from disruptions to the thoracic duct or its tributaries. This milky fluid, rich in triglycerides and lymphocytes, is integral to the body’s lymphatic system and nutrient transport. Chylothorax can stem from both traumatic events, such as surgical complications, and nontraumatic conditions, with malignancy representing a significant nontraumatic cause. The presence of chyle in the pleural space poses serious clinical challenges, potentially leading to respiratory distress, nutritional deficiencies, and immunological compromise due to lymphocyte depletion. Therefore, accurate and timely Chylothorax Diagnosis is paramount for effective patient management.

This article provides an in-depth review of chylothorax diagnosis and management, outlining current diagnostic modalities and therapeutic strategies ranging from conservative measures to surgical interventions. We aim to equip healthcare professionals with a thorough understanding of chylothorax, encompassing its etiology, pathophysiology, and, crucially, the methods for definitive chylothorax diagnosis. Furthermore, we will explore the collaborative role of an interprofessional healthcare team in optimizing patient outcomes in the complex landscape of chylothorax management.

Etiology of Chylothorax

The causes of chylothorax are broadly categorized into nontraumatic, traumatic, and idiopathic origins. While historically, nontraumatic causes were more prevalent, recent data indicates a shift towards traumatic chylothorax, particularly postoperative cases, as the predominant etiology.

Nontraumatic Chylothorax

Nontraumatic chylothorax encompasses a range of underlying conditions:

• Congenital Chylothorax: This form can present as an isolated anomaly or in conjunction with broader lymphatic system abnormalities, including lymphangiectasis, lymphangiomatosis, tuberous sclerosis, congenital heart defects, and chromosomal disorders like Trisomy 21 or Turner syndrome.
• Neoplastic Chylothorax: Malignancy stands as the most frequent cause of nontraumatic chylothorax. Various cancers have been implicated, notably lymphoma, chronic lymphocytic leukemia, lung cancer, esophageal cancer, and metastatic carcinomas. Interestingly, the incidence of chylothorax in lymphoma patients has seen a relative decline, potentially due to earlier lymphoma detection and treatment, mitigating late-stage complications like chylothorax.
• Infectious Chylothorax: Predominantly observed in developing nations, infectious chylothorax often arises as a complication of tuberculous lymphadenitis. Other infectious agents, such as aortitis, histoplasmosis, and filariasis, can also contribute to its development.
• Rare Causes: A spectrum of less common conditions has been linked to chylothorax, including Castleman disease, sarcoidosis, Kaposi sarcoma, yellow nail syndrome, Noonan syndrome, Down syndrome, Waldenström macroglobulinemia, amyloidosis, venous thrombosis, thoracic radiation, and goiter. These diverse conditions share a common mechanism: the potential to obstruct or damage the thoracic duct, ultimately leading to chyle leakage and chylothorax.

Traumatic Chylothorax

Traumatic chylothorax results from physical disruption of the thoracic duct anywhere along its mediastinal course. This damage can be iatrogenic, occurring as a complication of surgical procedures, or due to non-surgical trauma such as blunt or penetrating chest injuries.

• Postoperative Chylothorax: In contemporary medicine, postoperative chylothorax represents the most common form of traumatic chylothorax. The risk varies significantly depending on the surgical procedure. Esophagectomy carries the highest risk, with reported incidences ranging from 5% to 10%. Lung resection involving mediastinal lymph node dissection follows with a 3% to 7% risk. Other surgeries in the mediastinum, lower neck, or involving thoracic aneurysms, sympathectomy, and mediastinal tumors also pose a risk of chylothorax.
• Nonsurgical Posttraumatic Chylothorax: Procedures like central line placement, pacemaker implantation, and embolization of pulmonary arteriovenous malformations can inadvertently cause thoracic duct injury and subsequent chylothorax.
• Penetrating and Blunt Trauma: Direct thoracic duct injury can occur from penetrating chest wounds, such as gunshot or stab wounds. Blunt chest trauma or thoracic spine injuries can also disrupt the thoracic duct, even without apparent damage to surrounding structures, leading to chylothorax.
• Miscellaneous Trauma: Less frequent causes include blasting injuries and even seemingly minor events like forceful coughing or sneezing, which have been reported to trigger chylothorax in rare instances.

Idiopathic Chylothorax

In approximately 10% of chylothorax cases, the etiology remains undetermined, classified as idiopathic chylothorax. While esophageal resection is considered a common iatrogenic cause, spontaneous cases, including those occurring during pregnancy or triggered by labor, have also been documented.

Epidemiology of Chylothorax

Chylothorax is a relatively rare condition, regardless of its traumatic or nontraumatic origin, accounting for up to 3% of all pleural effusions. Traumatic cases are now more frequently encountered than nontraumatic ones. Iatrogenic chylothorax is a particular concern in thoracic surgeries, especially esophageal procedures, due to the thoracic duct’s anatomical proximity and variability. The incidence of iatrogenic chylothorax in esophageal resections can be as high as 4%.

Among nontraumatic causes, malignancy is the most prevalent, contributing to nearly one-third of all chylothorax cases. Lymphoma is responsible for the majority (70% to 75%) of malignant chylothorax, with non-Hodgkin lymphoma being the most common subtype. Metastatic epithelial tumors can also cause chylothorax, although less frequently. Other nontraumatic causes collectively account for about one-fifth of all chylothorax cases.

Pathophysiology of Chylothorax

A fundamental understanding of the lymphatic system’s anatomy is essential for comprehending chylothorax pathophysiology.

Anatomy of the Lymphatic System

The lymphatic system is a complex network comprising lymphatic vessels, lymph nodes, and the cisterna chyli. The thoracic duct serves as the principal collecting vessel, draining approximately three-quarters of the body’s lymph into the venous circulation. It originates from the cisterna chyli, a dilated lymphatic sac situated in the retroperitoneum near the second lumbar vertebra.

Ascending through the aortic hiatus of the diaphragm, the thoracic duct traverses the posterior mediastinum, positioned between the descending thoracic aorta and the azygos vein. At the level of the fifth thoracic vertebra, it shifts leftward into the superior mediastinum, continuing its ascent behind the aortic arch and the left subclavian artery, adjacent to the esophagus and left pleura. Finally, it typically terminates by emptying into the junction of the left subclavian and internal jugular veins, although anatomical variations in its termination are common. The thoracic duct’s length in adults ranges from 38 to 45 cm, with a diameter of 3 to 5 mm at its origin, narrowing mid-thorax and slightly dilating again before termination.

Any breach in the thoracic duct’s integrity along its mediastinal course will result in chyle leakage into the pleural cavity, leading to chylothorax.

Composition of Chyle

Chyle is a complex fluid composed of chylomicrons (aggregates of long-chain triglycerides, cholesterol esters, and phospholipids), lymphocytes (predominantly T lymphocytes), electrolytes, immunoglobulins, and fat-soluble vitamins. Its electrolyte concentration is similar to plasma, but it is notably rich in lipids and immune components.

History and Physical Examination in Chylothorax Diagnosis

Clinical presentation of chylothorax varies depending on the underlying cause and the volume of pleural effusion. Small chylothoraces may be asymptomatic and discovered incidentally during imaging for other reasons. Larger effusions typically manifest with symptoms related to lung compression and impaired respiratory function.

Progressive dyspnea is a common complaint, limiting exercise capacity. Patients may experience chest pressure, although fever and chest pain are usually absent. Notably, significant chyle accumulation can occur gradually without pronounced symptoms if the respiratory system adapts over time. Posttraumatic chylothorax may present days after the initial injury, sometimes up to 10 days. In postoperative settings, chylothorax is often initially suspected due to pleural effusion on routine imaging or persistent drainage from chest tubes.

Physical examination findings may include decreased breath sounds and dullness to percussion on the affected side, depending on the effusion size and location. Unilateral chylothorax is observed in approximately 80% of cases, with right-sided effusions being more frequent (two-thirds of unilateral cases) due to the thoracic duct’s anatomical course.

Evaluation and Chylothorax Diagnosis

The diagnostic evaluation of chylothorax is crucial for confirming the presence of chyle in the pleural space and guiding appropriate management. The diagnostic process typically involves a combination of imaging studies and pleural fluid analysis.

Chest Radiograph

Chest radiography is often the initial imaging modality used to evaluate dyspnea, particularly in postoperative and trauma patients. It can detect pleural effusions, including chylothorax, which typically appears as a homogeneous density obliterating the costophrenic and cardiophrenic angles. However, chest radiographs are nonspecific and cannot differentiate chylothorax from other causes of pleural effusion.

Alt text: Chest X-ray illustrating homogeneous density indicative of pleural effusion, a preliminary finding in chylothorax diagnosis, requiring further investigation.

Thoracic Ultrasound

Thoracic ultrasound is increasingly utilized in evaluating pleural pathologies. Chylothorax, similar to other pleural effusions, appears as an isodense or echoic region without septations or loculations on ultrasound. Like chest radiography, ultrasound is sensitive for detecting pleural fluid but lacks specificity in chylothorax diagnosis and cannot distinguish it from other effusion types.

Computed Tomography (CT) of the Chest

CT scanning of the chest is more sensitive than radiographs and ultrasound for detecting pleural effusions and can provide valuable information for chylothorax diagnosis. While the cisterna chyli is visualized on routine chest CT in only a small percentage of cases (around 2%), CT can reveal characteristic features suggestive of chylothorax. Due to its high fat content, chyle may appear as a low-attenuation tubular area in the posterior mediastinum. Importantly, CT can also help identify underlying causes of chylothorax, such as mediastinal masses, thoracic malignancies, or evidence of trauma.

Magnetic Resonance Imaging (MRI) of the Chest

MRI is highly sensitive for visualizing the cisterna chyli, reportedly depicting it in 100% of cases. While MRI can be used to evaluate chylothorax, it is not routinely employed for thoracic pathology assessment due to its limitations compared to CT in imaging lung parenchyma and bony structures. Therefore, MRI plays a less prominent role in routine chylothorax diagnosis compared to CT.

Conventional Lymphangiography

Conventional lymphangiography is a specialized imaging technique designed to visualize the lymphatic system directly. In this procedure, a contrast dye (historically methylene blue) is injected into lymphatic vessels, typically in the feet, allowing for fluoroscopic tracking of lymphatic flow. Lymphangiography can effectively identify thoracic duct leaks responsible for chylothorax. However, due to its invasiveness and the availability of less invasive yet accurate alternatives, conventional lymphangiography is now rarely used for chylothorax diagnosis in modern practice.

Nuclear Lymphoscintigraphy

Nuclear lymphoscintigraphy is a less invasive nuclear medicine technique that has gained favor over conventional lymphangiography for lymphatic system imaging. It involves subcutaneous injection of a radiotracer (Tc99m-labeled human diethylenetriaminepentaacetic acid) into the feet. Sequential imaging with a gamma camera allows for visualization of lymphatic pathways and identification of chyle leaks. Lymphoscintigraphy can be combined with SPECT/CT imaging for enhanced anatomical localization of leaks. Studies have shown good correlation between lymphoscintigraphy, conventional lymphangiography, and surgical findings in leak localization, making it a valuable tool in chylothorax diagnosis.

Pleural Fluid Analysis: The Cornerstone of Chylothorax Diagnosis

Pleural fluid analysis obtained via thoracentesis is the definitive diagnostic test for chylothorax. Fluid samples should undergo comprehensive analysis, including:

• Cell Count and Differential: Chyle is characteristically lymphocyte-rich, with lymphocytes typically comprising over 80% of the cellular component. These are predominantly polyclonal T cells.

• Glucose, Lactate Dehydrogenase (LDH), Total Protein: These parameters help characterize the fluid as exudative or transudative, although chylothorax is typically exudative.

• Cytology and Microbiology: Routine cytology is performed to rule out malignancy, particularly if neoplastic chylothorax is suspected. Microbiology studies (smear and culture) are indicated to exclude infectious etiologies.

• pH: Chylous fluid is typically alkaline, with a pH ranging from 7.4 to 7.8.

• Lipid Analysis: Triglycerides and Chylomicrons: This is the critical component for chylothorax diagnosis.

  • Triglyceride Level: A pleural fluid triglyceride concentration exceeding 110 mg/dL is highly suggestive of chylothorax. However, it’s important to note that approximately 15% of chylothorax cases may have triglyceride levels below this threshold, influenced by factors like recent meals and dietary fat intake.
  • Lipoprotein Electrophoresis: If clinical suspicion for chylothorax remains high despite lower triglyceride levels, lipoprotein electrophoresis should be performed. The detection of chylomicrons in pleural fluid definitively confirms chylothorax diagnosis.
  • Cholesterol Level: In contrast to pseudochylothorax, the total cholesterol level in true chylothorax is typically less than 200 mg/dL.

• Gross Appearance and Centrifugation:

  • Color: Chylous fluid classically appears milky white or opalescent due to its fat content. However, it can also be serous or serosanguineous, particularly in cases with lower chyle volumes or chronic effusions. Therefore, the absence of a milky appearance does not exclude chylothorax diagnosis.
  • Centrifugation: After centrifugation, chylous pleural fluid supernatant remains opaque, whereas supernatant from non-chylous effusions (excluding cholesterol effusions and empyema) typically becomes clearer. This opacity results from suspended leukocytes and lipid debris in chyle.

Pseudochylothorax (Chyliform Effusion)

Pseudochylothorax, or chyliform effusion, represents a differential diagnostic consideration. These effusions are milky-white in appearance, mimicking chylothorax, but are distinct in their composition. Pseudochylothorax is characterized by high cholesterol content rather than triglycerides and chylomicrons. It typically arises from long-standing exudative pleural effusions associated with chronic conditions like tuberculosis and rheumatoid pleuritis. In these conditions, cholesterol released from cell membranes accumulates in the pleural space, imparting a milky appearance.

Key differentiating features of pseudochylothorax compared to true chylothorax include:

• Cholesterol Level: Elevated, typically exceeding 200 mg/dL.
• Triglyceride Level: Low, usually below 110 mg/dL.
• Cholesterol-to-Triglyceride Ratio: Always greater than 1.
• Absence of Chylomicrons: Lipoprotein electrophoresis will not detect chylomicrons.
• Cholesterol Crystals: Microscopic examination of dried pleural fluid under polarized light may reveal characteristic cholesterol crystals, appearing as rectangular plates with notched edges, which are virtually diagnostic of pseudochylothorax.

Treatment and Management of Chylothorax

Management of chylothorax is tailored to the underlying cause, severity, and patient’s clinical status. Treatment strategies range from conservative approaches to more invasive interventions.

Dietary Therapy

Dietary modification is a cornerstone of conservative chylothorax management. Reducing dietary long-chain triglycerides minimizes chyle production, promoting spontaneous leak closure. A very low-fat diet (less than 5 kcal of fat per meal) is often recommended. To mitigate potential fat deficiencies and malnutrition associated with long-term fat restriction, medium-chain triglycerides (MCTs) can be incorporated into the diet, as MCTs are absorbed directly into the portal venous system, bypassing lymphatic circulation and minimizing chyle formation. Intravenous supplementation of long-chain fatty acids may be considered to address essential fatty acid deficiencies if prolonged dietary fat restriction is necessary.

Thoracentesis and Drainage

Therapeutic thoracentesis can be used intermittently to relieve symptomatic pleural effusions, particularly in nontraumatic and nonsurgical traumatic chylothorax. Indwelling pleural catheters can facilitate continuous drainage, especially in outpatient settings. However, prolonged pleural fluid drainage can lead to significant protein and immunoglobulin loss, increasing the risk of malnutrition and infection. Continuous drainage is generally limited to less than two weeks. Surgical intervention is often considered if daily pleural fluid drainage exceeds 1.5 liters. In postoperative chylothorax, chest tube drainage is typically the initial management strategy.

Pleurodesis

Pleurodesis is indicated for patients with persistent chylothorax despite dietary modifications and repeated drainage procedures. Chemical pleurodesis, often using talc insufflation during video-assisted thoracoscopic surgery (VATS), aims to obliterate the pleural space, preventing fluid reaccumulation. Pleurodesis can be effective in up to 80% of chylothorax cases. Thoracic duct ligation can be performed concomitantly with surgical pleurodesis to address the source of chyle leak and enhance treatment success.

Thoracic Duct Ligation

Thoracic duct ligation, typically performed via VATS, is a surgical intervention considered for patients who fail to respond to conservative measures like dietary therapy and pleurodesis. Ligation effectively eliminates chyle leakage from the thoracic duct into the pleural space. While lymphedema is a potential complication, it often resolves over time due to the development of lymphatic-venous collateral circulation.

Thoracic Duct Embolization and Disruption

Percutaneous thoracic duct embolization and disruption are minimally invasive techniques increasingly used for both traumatic and nontraumatic chylothorax. The procedure involves pedal lymphangiography to visualize the lymphatic system, followed by transabdominal needle cannulation of the cisterna chyli. Contrast is injected to localize the chyle leak, and the affected thoracic duct segment is then embolized using coils and surgical glues to occlude the leak.

Emerging Therapies

• Somatostatin and Octreotide: These somatostatin analogs reduce gastrointestinal secretions (gastric, pancreatic, biliary), thereby decreasing lymphatic flow and chyle production. They can promote spontaneous closure of thoracic duct leaks and have shown efficacy in various types of chylothorax, including spontaneous, congenital, postoperative, and malignancy-related cases. Optimal dosing and treatment duration are still under investigation.
• Sirolimus: This mTOR inhibitor, used primarily in lymphangiomyomatosis treatment, has also demonstrated a reduction in chylothorax incidence in these patients.
• Shunting Procedures: Pleurovenous or pleuroperitoneal shunts can divert chylous pleural fluid into the venous system or peritoneal cavity, respectively. Pleuroperitoneal shunts include the Denver shunt (active pump) and LeVeen shunt (passive pump). Shunting offers the advantage of recycling nutrient-rich chyle back into the body. Pleurovenous shunting, draining chyle from the pleural space to the subclavian or jugular vein, has been successfully used in yellow nail syndrome and postoperative chylothorax.

Differential Diagnosis of Chylothorax

Accurate chylothorax diagnosis requires considering a range of differential diagnoses that can present with similar clinical features and pleural effusions. Distinguishing chylothorax from these conditions is crucial for appropriate management. Key differential diagnoses include:

• AIDS-related complex
• Congestive heart failure
• Thoracic empyema
• Exudative pleural effusion (non-chylous)
• Hemothorax
• Malignant pleural effusion (non-chylous)
• Parapneumonic pleural effusion
• Pseudochylothorax (chyliform effusion)

Prognosis of Chylothorax

Chylothorax, while uncommon, can be a significant complication, particularly following cardiothoracic surgery. Prognosis varies depending on the underlying etiology and the effectiveness of treatment. Chylothorax associated with benign causes generally carries a more favorable prognosis compared to malignancy-related chylothorax.

A staged care approach, progressing from conservative to invasive therapies, is often beneficial. The Esophagectomy Complications Consensus Group (ECCG) has developed a classification system for chyle leaks following esophagectomy, categorizing leaks based on treatment response and output volume, which aids in guiding management strategies and predicting prognosis in this specific context. Conservative management, including dietary modifications and TPN, is often successful for lower-grade leaks (ECCG type I and II). The role of somatostatin analogs like octreotide in managing chyle leaks, particularly after esophageal resection, is still being investigated.

Complications of Chylothorax

Untreated or poorly managed chylothorax can lead to significant complications:

• Malnutrition: Loss of chyle, rich in fats, proteins, and fat-soluble vitamins, can result in malnutrition, weight loss, and muscle wasting.
• Immunosuppression: Lymphocyte depletion in chyle can impair immune function, increasing susceptibility to infections.
• Respiratory Distress: Persistent pleural effusions compromise lung function and cause dyspnea.
• Electrolyte Imbalance and Fluid Depletion: Prolonged chyle leakage can disrupt fluid and electrolyte balance.

Effective management strategies, including nutritional support, infection prevention, and careful monitoring of fluid and electrolytes, are essential to mitigate these complications.

Deterrence and Patient Education

Preventive measures and patient education play a crucial role in minimizing chylothorax risk and optimizing patient outcomes. For patients undergoing thoracic surgery, meticulous surgical technique to avoid thoracic duct injury is paramount. In the postoperative period, early recognition of pleural effusions and prompt chylothorax diagnosis are essential.

Patient education should focus on:

• Dietary Adherence: Emphasizing the importance of low-fat diets and MCT supplementation to reduce chyle production.
• Early Symptom Recognition: Educating patients to recognize and report early signs of chylothorax recurrence or complications, such as increased shortness of breath or signs of infection.
• Long-Term Monitoring: Informing patients about the necessity of ongoing follow-up and adherence to their treatment plan.

Pearls and Key Issues in Chylothorax Management

• Early Diagnosis is Key: Prompt chylothorax diagnosis and intervention are crucial to prevent complications.
• Pleural Fluid Analysis is Definitive: Triglyceride levels and chylomicron detection in pleural fluid are essential for confirming chylothorax diagnosis.
• Dietary Modification is First-Line: Low-fat diets with MCT supplementation are fundamental in conservative management.
• Multidisciplinary Approach: Effective chylothorax management requires a collaborative team, including pulmonologists, thoracic surgeons, dietitians, and other specialists.
• Monitor for Complications: Vigilance for malnutrition and immunosuppression is crucial throughout chylothorax management.
• Somatostatin Analogs: Somatostatin and octreotide are valuable adjuncts in medical management.

Enhancing Healthcare Team Outcomes in Chylothorax Management

Optimal outcomes in chylothorax management are achieved through a well-coordinated interprofessional team approach. This team typically includes pulmonologists, thoracic surgeons, dietitians, internists, intensivists, advanced practice providers, nurses, and pharmacists.

Effective teamwork requires:

• Clear Roles and Responsibilities: Each team member should have a defined role in patient care.
• Open Communication: Regular case discussions and multidisciplinary meetings facilitate shared decision-making and care coordination.
• Shared Documentation: Accessible and comprehensive patient records ensure continuity of care.
• Integrated Care Plan: A cohesive care plan addresses both immediate and long-term patient needs, from initial chylothorax diagnosis to ongoing management and follow-up.

By fostering a collaborative and communicative environment, healthcare teams can optimize patient safety, enhance patient-centered care, and improve outcomes in the complex management of chylothorax.

Review Questions

Figure

Chest X-Ray Showing Chylothorax With Homogeneous Density. Contributed by S Bhimji, MD.

References

1.Schild HH, Pieper C. [Chylothorax: Current Therapeutic Options]. Zentralbl Chir. 2019 Sep;144(S 01):S24-S30. [PubMed: 30795028]
2.Zhang C, Xi MY, Zeng J, Li Y, Yu C. Prognostic Impact of Postoperative Complications on Overall Survival in 287 Patients With Oral Cancer: A Retrospective Single-Institution Study. J Oral Maxillofac Surg. 2019 Jul;77(7):1471-1479. [PubMed: 30790530]
3.Iio K, Soneda K, Shimotakahara A, Hataya H, Kono T. Effective method of evaluating infantile chylothorax. Pediatr Int. 2019 Feb;61(2):203-205. [PubMed: 30767369]
4.Hayashi K, Hanaoka J, Ohshio Y, Igarashi T. Chylothorax secondary to a pleuroperitoneal communication and chylous ascites after pancreatic resection. J Surg Case Rep. 2019 Jan;2019(1):rjy364. [PMC free article: PMC6344917] [PubMed: 30697412]
5.Agrawal A, Chaddha U, Kaul V, Desai A, Gillaspie E, Maldonado F. Multidisciplinary Management of Chylothorax. Chest. 2022 Dec;162(6):1402-1412. [PubMed: 35738344]
6.Cherian S, Umerah OM, Tufail M, Panchal RK. Chylothorax in a patient with HIV-related Kaposi’s sarcoma. BMJ Case Rep. 2019 Jan 22;12(1) [PMC free article: PMC6347950] [PubMed: 30674495]
7.Yamagata Y, Saito K, Hirano K, Oya M. Laparoscopic Transhiatal Thoracic Duct Ligation for Chylothorax after Esophagectomy. Thorac Cardiovasc Surg. 2019 Oct;67(7):606-609. [PubMed: 30669171]
8.Gurevich A, Hur S, Singhal S, DiBardino D, Haas AR, Hansen-Flaschen JH, Nadolski G, Itkin M. Nontraumatic Chylothorax and Chylopericardium: Diagnosis and Treatment Using an Algorithmic Approach Based on Novel Lymphatic Imaging. Ann Am Thorac Soc. 2022 May;19(5):756-762. [PubMed: 34797746]
9.Dar PMUD, Gamanagatti S, Priyadarshini P, Kumar S. Traumatic chylothorax: a dilemma to surgeons and interventionists. BMJ Case Rep. 2021 May 21;14(5) [PMC free article: PMC8144052] [PubMed: 34020985]
10.Martínez Camacho RJ, Martínez Camacho LI, Martínez Camacho D, Martínez Camacho A. Idiopathic Chylothorax During Pregnancy: A Case Report. Cureus. 2023 Oct;15(10):e47841. [PMC free article: PMC10611550] [PubMed: 37899891]
11.Ur Rehman K, Sivakumar P. Non-traumatic chylothorax: diagnostic and therapeutic strategies. Breathe (Sheff). 2022 Jun;18(2):210163. [PMC free article: PMC9584559] [PubMed: 36337134]
12.Bhatnagar M, Fisher A, Ramsaroop S, Carter A, Pippard B. Chylothorax: pathophysiology, diagnosis, and management-a comprehensive review. J Thorac Dis. 2024 Feb 29;16(2):1645-1661. [PMC free article: PMC10944732] [PubMed: 38505027]
13.Papoulidis P, Vidanapathirana P, Dunning J. Chylothorax, new insights in treatment. J Thorac Dis. 2018 Nov;10(Suppl 33):S3976-S3977. [PMC free article: PMC6297462] [PubMed: 30631531]
14.Pospiskova J, Smolej L, Belada D, Simkovic M, Motyckova M, Sykorova A, Stepankova P, Zak P. Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders. Orphanet J Rare Dis. 2019 Jan 09;14(1):9. [PMC free article: PMC6327395] [PubMed: 30626415]
15.Yang RF, Liu TT, Wang P, Zhang RQ, Li C, Han B, Gao XX, Zhang L, Jiang ZM. Ligation of thoracic duct during thoracoscopic esophagectomy can lead to decrease of T lymphocyte. J Cancer Res Ther. 2018;14(7):1535-1539. [PubMed: 30589035]
16.Furukawa M, Hara A, Miyazaki R, Yokoyama S, Hayashi M, Tao H, Okabe K. [Assessment of Fat-free Diet for Postoperative Chylothorax]. Kyobu Geka. 2018 Dec;71(13):1063-1065. [PubMed: 30587742]
17.Santos LLD, Santos CLD, Hu NKT, Datrino LN, Tavares G, Tristão LS, Orlandini MF, Serafim MCA, Tustumi F. Outcomes of Chylothorax Nonoperative Management After Cardiothoracic Surgery: A Systematic Review and Meta-Analysis. Braz J Cardiovasc Surg. 2023 Oct 06;38(6):e20220326. [PMC free article: PMC10552558] [PubMed: 37801640]
18.Costa KM, Saxena AK. Surgical chylothorax in neonates: management and outcomes. World J Pediatr. 2018 Apr;14(2):110-115. [PubMed: 29508361]
19.Power R, Smyth P, Donlon NE, Nugent T, Donohoe CL, Reynolds JV. Management of chyle leaks following esophageal resection: a systematic review. Dis Esophagus. 2021 Nov 11;34(11) [PMC free article: PMC8597908] [PubMed: 33723611]